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Abstract: Early cancer detection is a major factor in the reduction of mortality and cancer 
management cost. Here we developed a smart and targeted micelle-based contrast agent for 
magnetic resonance imaging (MRI), able to turn on its imaging capability in the presence of 
acidic cancer tissues. This smart contrast agent consists of pH-sensitive polymeric micelles 
formed by self-assembly of a diblock copolymer (poly(ethyleneglycol-b-trimethylsilyl 
methacrylate)), loaded with a gadolinium hydrophobic complex (tBuBipyGd) and exploits the 
acidic pH in cancer tissues. In vitro MRI experiments showed that tBuBipyGd-loaded micelles 
were pH-sensitive, as they turned on their imaging capability only in an acidic microenviron-
ment. The micelle-targeting ability toward cancer cells was enhanced by conjugation with 
an antibody against the MUC1 protein. The ability of our antibody-decorated micelles to be 
switched on in acidic microenvironments and to target cancer cells expressing specific antigens, 
together with its high Gd(III) content and its small size (35–40 nm) reveals their potential use 
for early cancer detection by MRI.
Keywords: micelle, pH-sensitive, self-assembly, smart contrast agent, cancer detection
Introduction
The recent developments in imaging techniques such as computed tomography, 
fluorescence imaging, positron emission spectroscopy, and magnetic resonance imaging 
(MRI) have led to major advances in the field of biomedical diagnosis and therapy. 
Currently, MRI is one of the most powerful diagnostic techniques for molecular imag-
ing, mainly due to its noninvasive nature allied to other benefits, such as the ability to 
obtain direct multiplanar images, differentiate soft tissues, and obtain anatomical data 
while avoiding ionizing radiation. In addition, MRI allows sub-millimeter spatial resolu-
tion and has an excellent contrast resolution.1 However, in terms of sensitivity, MRI still 
lags behind other imaging tools. For example, MRI has a sensitivity of approximately 
10-3 mol L-1 to 10-5 mol L-1, which compared to other types of imaging, can be very 
limiting. Also, because healthy and pathological tissues as well as distinct diseases 
show similar magnetic moments, they produce a poor image contrast. Thus, in order 
to overcome these shortcomings and obtain more informative images, a substantial 
quantity of contrast agent (CA) needs to be injected.2 CA molecules are paramagnetic 
chemical substances that act by shortening the longitudinal and transversal relaxation 
times of water protons, T
1
 and T
2
, respectively. The most frequently used in clinical 
MRI are small molecules of Gd(III) chelates, which are T
1
 agents that due to their low 
molecular weight can distribute uniformly to all perfused tissues throughout the vas-
culature and can diffuse across endothelial wall vessels into the extracellular spaces.1,2 
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Free Gd(III) is toxic because its diameter is close to that of 
calcium ions and, for this reason, it has to be chelated to a 
ligand. These ligands reduce Gd(III) toxicity significantly and 
influence the pharmacokinetics of the complex.3 Then again, 
these low-molecular weight CAs suffer from some weak-
nesses such as lack of selectivity toward particular organs 
or pathological areas, absence of response toward cellular 
microenvironment, short half-life in blood (a large part of 
administered CA is eliminated before images are taken), and 
potential toxic side effects for some patients.4
Recently, scientists have developed new classes of medi-
cal imaging probes with low molecular weight called MRI 
smart CAs to overcome the classic CAs limitations. Unlike 
standard CAs, which enhance MR image constantly, smart 
CAs change between two states, depending on the type of the 
stimulus.5,6 This change is detected as an alteration in signal, 
because one of the states has low or no enhancement effect 
(“off state”), while the other induces a high enhancement 
(“on state”). These stimulus-sensitive agents can be detected 
when switching from one state to another after exposure to 
a metabolic or physiological event in a specific molecular 
target. A variety of smart CAs have been developed that 
become activated in response to changes in pH,7–13 to the pres-
ence of metal ions14–16 through enzymatic activation,17 and 
to the presence of oxygenated hemoglobin18 or radicals19 or 
upon exposure to ultrasounds20 or changes in temperature.21,22 
These smart CAs have proven to be excellent MRI tools for 
very specific targets in vitro and in vivo.7,8 On the other hand, 
targeted nanoparticles such as liposomes,23 dendrimers,24 
and micelles provide several unique features and capabili-
ties such as to house a large number or different types of 
functional groups that can be used in multiple diagnostic 
(eg, gadolinium complex) and therapeutic (eg, anticancer) 
agents. Moreover, nanoparticles with the size ranging from 
10 nm to 100 nm accumulate preferentially at tumor sites 
through an effect called enhanced permeability and reten-
tion.25 Finally, the capability of these nanoparticles of 
encapsulating a large amount of molecules (eg, gadolinium 
complex) inside their core will allow the detection of cancer 
at early stages (0, I, and II) due to the signal amplification 
generated by the large number of CAs released from the 
nanoparticles at the cancer tissue sites.
In this work, we aimed to develop a new type of smart 
CAs based on polymeric nanoparticles capable of ampli-
fying the MRI signal chemically and at the same time 
have the ability to remain silent during circulation and 
active at the target site. These newly developed nanopar-
ticle-based CAs consist of pH-sensitive polymeric stealth 
PEGylated micelles formed by self-assembly of a diblock 
copolymer, poly(ethyleneglycol-b-trimethylsilyl methacry-
late) (PEG-b-PTMSMA), loaded with the hydrophobic 
complex tetraaquodichloro(4,4′-di-t-butyl-2,2′-bipyridine)
gadolinium(III) chloride (tBuBipyGd). To enhance the 
targeting ability of these polymeric nanoparticles toward 
cancer cells, we decorated micelles with monoclonal anti-
body (mAb) against the human MUC1 protein, which is 
aberrantly expressed in many epithelial cancers, including 
breast cancer.26,27
Materials and methods
reagents and equipment
Ethanol (96%) was from AGA, tetrahydrofuran (THF), HPCL 
grade, from Ridel-de-Haën, hydrochloric acid (37%) from 
Merck, N,N-dimethylformamide (DMF) and isopropanol from 
BDH Prolabo, methoxypolyethylene glycol N-hydroxysuc-
cinimide ester and paraformaldehyde from Sigma-Aldrich, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) from Applichem, and Trizol reagent from 
Invitrogen. For cell culture, complete Dulbecco’s Modified 
Eagle’s Medium or RPMI1640 culture media (DMEM or 
RPMI1640 basic medium [Lonza] supplemented with 10% 
fetal bovine serum [PAA], 2 mM glutamine, 100 units mL-1 
penicillin, and 100 μg mL-1 streptomycin) were prepared. 
We purchased mAbs against the human MUC1 protein, C595 
(Santa Cruz Biotechnology) and SM3 (eBioscience), and 
phycoerythrin-conjugated goat anti-mouse secondary anti-
body (Biolegend). Oligonucleotide primers were synthesized 
by Sigma-Aldrich. Milli-Q water (Millipore) was used in all 
procedures. For dialysis, cassettes were purchased from Pierce 
Biotech, 10-kDa MWCO. For 1H nuclear magnetic reso-
nance (NMR) experiments, a Bruker ARX 400 (400 MHz) 
spectrometer was used, and MR images were obtained in 
a Signa 1.5T SYS#GEMSOW, GE Healthcare, clinical 
MRI. Fourier transform infrared spectroscopy spectrum was 
recorded in a KBr pellet within the range of 4,000–600 cm-1 
in a Bruker, Tensor 27 spectrophotometer. Elemental analy-
sis was performed on a Truspec 630-200-200 apparatus. 
Steady-state fluorescence spectra were recorded on a SPEX 
Fluoromax-3 spectrofluorometer (Jobin Yvon–Horiba). All 
emission spectra were carried out in 1-cm quartz cuvettes 
(Hellma Quartz-Suprasil), using λ
exc
 =334 nm, collecting 
the emission from 360 nm to 510 nm (increment of 1 nm), 
using 1-nm slit widths in excitation and emission (wavelength 
resolution of 1 nm), and corrected for nonlinear instrument 
response. For MTT assays, a Tecan Infinite M200 mono-
chromator-based multifunction microplate reader was used. 
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Nucleic acid concentration was determined on a NanoDrop 
2000c  Spectrophotometer (Thermo Scientific). Polymerase 
chain reaction (PCR) amplification was performed on a 
CFX96 Real-Time PCR Detection System (Bio-Rad). Flow 
cytometry was performed on a FACS Calibur analyzer, and 
data were processed with Cell Quest software (BD Biosci-
ences). White light and fluorescence observation and image 
acquisition of living cells was performed with an inverted fluo-
rescence microscope (Leica DM IL) coupled to a digital CCD 
camera (Evolution MP-5.1, Media Cybernetics). Observation 
and image acquisition of fixed cells was performed on an Axio 
Observer Z2 Fluorescence microscope (Zeiss), coupled to a 
digital AxioCam camera (Zeiss). Images were processed using 
AxioVision software (Zeiss). All light-scattering experiments 
were performed using Brookhaven Instruments BI-200SM 
Multiangle DLS & SLS Light Scattering System.
Diblock co-polymer synthesis
The macro-CTA weighing 0.8 g was placed in a Schlenk 
tube, previously charged with nitrogen and dissolved in 
10 mL of THF. A volume of 3.5 mL (45 eq) of trimethylsilyl 
methacrylate and 0.030 g (1 mol% of the monomer) of 
AIBN were added. After three freeze–pump–thaw cycles, 
the mixture was incubated in an oil bath at 60°C, under 
stirring, for 24 hours. The flask was then cooled to room 
temperature, 10 mL of THF added to dilute the mixture, 
which had become very viscous, and its content transferred 
to a round-bottomed flask. After evaporation of the solvent, 
the white residue was dissolved in methanol and the poly-
mer precipitated by the addition of water. The polymer was 
separated from the supernatant by centrifugation at 15,344× g 
during 30 minutes, followed by decantation (Figure 1A). This 
procedure was repeated one more time, affording a white solid 
that was vacuum dried, at 60°C, overnight, yielding 1.47 g 
(40%) 1H NMR (DMSO) δ 0.056 (s, (CH
3
)
3
Si), 1.086 (s, 
CH
3
C–C=O), 1.177 (s, CH
3
C–C=O), 1.878 (s, CH
2
C–C=O), 
1.992 (s, CH
2
C–C=O), 3.356 (s, CH
3
O–(CH
2
CH
2
O)
n
), 3.639 
(s, (CH
2
CH
2
O)
n
), and 4.660 (q, CH
3
CH
2
O–C=S); DP
n
 
(NMR) =45. Gel permeation chromatography (GPC) analysis 
(PSSNa standards) reveals a monomodal molecular weight dis-
tribution, from which a value of M
n
 =9 kDa was predicted.28
Preparation of tBuBipygd complex
The preparation of this complex (Figure 1B) was based 
on a well-described method.29,30 A mixture of 0.500 g 
(0.830 mmol) of GdCl
3
⋅4H
2
O and 0.223 g (0.830 mmol) 
of tBuBipy in 25 mL of ethanol was stirred and refluxed 
overnight. The resulting solution was concentrated, and the 
final product was obtained by the addition of diethyl ether. 
The white solid was washed with diethyl ether to remove 
unreacted tBuBipy and dried under reduced pressure to afford 
0.450 g (90%) of tBuBipyGd complex. Elemental analysis 
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Figure 1 (A) synthesis strategy of the co-polymer poly(ethyleneglycol-b-trimethylsilyl methacrylate); (B) synthesis strategy of tBuBipygd complex; and (C) encapsulation of 
contrast agent during the self-assembly of polymeric nanoparticles (micelles).
Abbreviations: ThF, tetrahydrofuran; h, hour; aIBN, azobisisobutyronitrile; DMsO, dimethyl sulfoxyde.
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theoretical values are as follows: 35.77% C; 5.34% H; 
4.64% N; and the obtained values were as follows: 35.99% C; 
5.59% H; 4.69% N. Fourier transform infrared spectroscopy 
(KBr) values were as follows: 2,963 cm-1 (s), 2,866 cm-1 (s), 
1,594 cm-1 (vs), 1,545 cm-1 (vs), 1,374 cm-1 (s), 837 cm-1 
(s), 605 cm-1 (s). To obtain a 50 mM stock solution, 5.1 mg 
of the complex was dissolved in 169 μL of ethanol. The 
solution was kept at -20°C.
Preparation of fluorophore-loaded and 
tBuBipygd complex-loaded polymeric 
micelles
Polymeric micelles loaded with tBuBipyGd complex were 
obtained as follows: 30 mg of PEG-b-PTMSMA and 0.5 mg of 
either 1-methylpyrene or tBuBipyGd complex was dissolved 
in 0.3 mL of DMF. The mixture was stirred for 3 hours at room 
temperature. Subsequently, 0.7–1.0 mL of pure Milli-Q water 
was added at a rate of one drop every 10 seconds to induce 
micellization. The resulting micelle solution was then dialyzed 
against 4 L of Milli-Q water for 3 days at room temperature, 
using a 10-kDa cut-off dialysis cassette to exclude unencap-
sulated compound or nonself-assembled polymer molecules. 
The Milli-Q water was replaced twice a day.
Measurement of gd(III) complex and 
fluorophore concentrations loaded in 
micelles
A 6.62×10-5 M stock solution of Gd(III) complex in 
ethanol was diluted to obtain standards with the following 
concentrations: 3.31×10-5 M, 1.66×10-5 M, 3.31×10-6 M, 
1.66×10-6 M, and 3.31×10-7 M, and then obtain a Gd(III) 
complex calibration curve (Figure 2A). The corresponding 
absorbance values were recorded at 282 nm, and the molar 
absorption coefficient was 1.28×104 dm3 mol-1 cm-1. From 
a 2.17×10-5 M stock solution of 1-methylpyrene in THF, 
five standards of concentrations 1.63×10-5 M, 1.09×10-5 M, 
8.68×10-6 M, 5.43×10-6, and 1.09×10-6 M were prepared and 
a 1-methylpyrene calibration curve was obtained (Figure 2B). 
The absorbance values were measured at 344 nm and a value 
of 3.01×104 dm3 mol-1 cm-1 for the molar absorption coeffi-
cient was obtained. For the determination of Gd(III) complex 
or fluorophore concentrations in loaded micelles, each solu-
tion was diluted (30 μL of solution to a total volume of 3 mL) 
in a spectrophotometer cuvette containing the appropriate 
solvent (ethanol for the former and THF for the latter) and the 
absorbance was read at 282 nm or 344 nm, respectively. The 
average concentration of tBuBipyGd complex in the micelles 
was 0.065 mM, which represents 70% yield of contrast 
encapsulation. The average concentration of 1-methylpyrene 
in micelle solution was found to be 0.96 mM.
Bioconjugation of polyethylene glycol with 
MUc1 antibodies
Bioconjugation of PEG with C595 or SM3 mAb was per-
formed as follows: 3 mg of methoxypolyethylene glycol 
N-hydroxysuccinimide ester was added to a solution con-
taining 3 μg of mAb in 0.1 M bicarbonate buffer (500 μL, 
pH 8.3). The mixture was gently stirred for 5 days in slow 
tilt rotation at 4°C.
Preparation of fluorophore-loaded 
bioconjugated micelles
Fluorophore-loaded bioconjugated micelles were prepared 
by mixing 30 mg of PEG-b-PTMSMA with 0.5 mg of 
A
A
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U
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B
Figure 2 relationship between the absorbance intensity and concentration of tBuBipygd complex and 1-methylpyrene at the optimum wavelength.
Notes: (A) absorbance of tBuBipygd complex at 282 nm. (B) absorbance of 1-methylpyrene at 344 nm.
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1-methylpyrene and dissolved in 0.4 mL of DMF. The 
mixture was stirred for 3 hours at room temperature. Sub-
sequently, 0.5 mL PEG-Anti-MUC1 aqueous solution was 
added at a rate of one drop every 10 seconds and, immediately 
after, 0.5 mL of cold Milli-Q water was added at the same rate 
to induce micellization. The resulting micelle solution was 
then placed in a dialysis cassette with a 10-kDa cut-off, to 
exclude unencapsulated compounds (either 1-methylpyrene 
or Gd complex) or possibly nonself-assembled polymer 
molecules and dialyzed against cold Milli-Q water for 3 
days at 4°C. The recovered solution was then centrifuged to 
remove the free PEG-Anti-MUC1 and then the pellet was 
diluted once again with Milli-Q water.
assessment of micelle stability in water 
and cell culture medium
1-Methylpyrene–loaded micelle solution (200 μL) was added 
to a cuvette containing 800 μL of either water or complete 
DMEM culture medium, and the fluorescence spectrum was 
acquired. The spectrum of 1-methylpyrene–loaded micelles 
bioconjugated with antibody in culture medium was also 
obtained.
Determination of the influence of 
tBuBipygd complex in the T1 value of water
tBuBipyGd complex–loaded micelle aqueous solution 
(10 μL) was placed in an NMR tube containing deuterated 
water, and T
1
 of water protons was measured using the inver-
sion recovery method. The sequence was [180°
x′ (16 μs) − τ 
(0.05, 0.25, 0.5, 1, 1.5, 2, 3, 5, and 10 seconds) − 90°
x′ 
(8 μs) − T
a
 (equal to τ) − D (12 seconds)]
8
. Subsequently, 
approximately 10 μL of acidic solution (pH 5.5) was added 
to the tube to induce micelle bursting, and thus tBuBipyGd 
complex release. The above procedure was repeated. Data 
were fit to an exponential, from which T
1
 values were derived, 
using Bruker Topspin 2.0 software.
Determination of the tBuBipygd complex 
imaging ability in vitro
To image tBuBipyGd complex released from micelles, the 
same volume of tBuBipyGd complex–loaded micelles in 
serum was dispensed in two microfuge tubes. Next, hydro-
chloric acid was added to only one of them to obtain approxi-
mately pH 5.5. Both tubes were positioned on top of an MRI 
phantom for calibration. MR images were subsequently 
acquired with a Spin Echo sequence (TR/TE=300/12 ms; 
slice thickness, 3 mm; field of view, 18×18 cm; matrix, 
256×256).
cell lines
The MCF-7 and MDA-MB-468 (human breast adenocar-
cinoma), HEK293T (Human Embryonic Kidney), and S17 
(mouse bone marrow stroma) cell lines were maintained 
in complete DMEM culture medium. The Jurkat (human 
T-cell leukemia) cell line was maintained in complete 
RPMI1640 culture medium. Cells were cultured at 37°C 
under humidified atmosphere of 5% CO
2
, unless stated 
otherwise.
In vitro cytotoxicity tests
Jurkat or MCF-7 cells were seeded on 96-well culture plates. 
Different concentrations (5 μM, 10 μM, 15 μM, and 20 μM) 
of tBuBipyGd complex buffer solution was added to the cul-
ture medium and incubated for 3 days. In addition, different 
concentrations of free and encapsulated tBuBipyGd complex 
(at concentrations of 10 μM or 50 μM) were added to the cells 
and incubated for 3 days. These assays included tBuBipyGd-
loaded micelles dialyzed for 3 days and also nonencapsulated 
micelles. After incubation, toxicity was evaluated by the 
MTT assay. Briefly, 10 μL of 5 mg mL-1 MTT solution was 
added to each well followed by further incubation for 4 hours. 
Then, 100 μL of 0.04 N HCl in isopropanol was added to 
the wells and formazan crystals were allowed to solubilize 
for 1 hour at room temperature. The formazan concentration 
was quantified by measuring the absorbance at 570 nm and 
630 nm. The final optical density was calculated following 
the formula: optical density = L
570 nm
-L
630 nm
, where L was the 
obtained absorbance value for each wavelength. The toxicity 
was assessed by calculating the percentage of cell survival 
in relation to the control untreated group. The results were 
statistically compared by Student’s t-test using GraphPad 
Prism software.
Detection of MUc1 expression by  
reverse-transcriptase Pcr and 
immunofluorescent flow cytometry
Total RNA was extracted from cultured cell lines using 
Trizol following the manufacturer’s instructions. The con-
centration and purity of isolated RNA was measured by 
spectrophotometry, and its quality assessed by agarose gel 
migration. RNA treated with RNase-free DNAse I (Fer-
mentas) was reversed transcribed using the RevertAid First 
Strand cDNA Synthesis Kit (Fermentas), and quantitative 
PCR was performed using the iQ SYBR-Green Supermix 
kit (Bio-Rad). Primers to detect expression of MUC1 and 
the ACTB reference gene were used at a 200 mM concen-
tration: MUC1-Forward, 5′-GTG CCC CCT AGC AGT 
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ACC G-3′; MUC1-Reverse, 5′-GAC GTG CCC CTA CAA 
GTT GG-3′; ACTB-Forward, 5′-AGG CCA ACC GCG 
AGA AGA TGA C-3′; and ACTB-Reverse, 5′-AGG TCC 
AGA CGC AGG ATG GCA T-3′. Relative mRNA expres-
sion levels were calculated through the 2-ΔΔCt method. For 
MUC1 protein detection by flow cytometry, HEK293T, 
MCF-7, and MDA-MB-468 cells were dissociated by 
0.02% EDTA treatment, washed, and labeled with SM3 
mAb (1/500 dilution), C595 mAb (1/100 dilution), or an 
isotypic nonspecific antibody and phycoerythrin-conjugated 
goat anti-mouse secondary antibody. Each antibody incuba-
tion was performed for 1 hour on ice and was followed by 
PBS/3% fetal bovine serum/5 mM NaN
3
 washes, before 
flow cytometry analysis.
assessment of polymeric micelle cellular 
uptake by microscopy
MCF-7 or MDA-MB-468 cells were seeded in cul-
ture plates and allowed to attach for 24 hours at 37°C. 
Micelles bioconjugated with C595 or SM3 antibody and 
loaded with 1-methylpyrene were added to the cells and 
incubated for 1 hour at 37°C. As a control, we used non-
conjugated 1-methylpyrene–loaded polymeric micelles. 
Excess micelles were removed by washing three times 
with PBS. For mixed cell cultures, MDA-MB-468 and 
S17 cells were either grown together (proportion of 1–5, 
respectively) or alone on glass cover slips. The cells were 
allowed to adhere for 24 hours at 37°C, and then, anti-
MUC1–conjugated 1-methylpyrene–loaded micelles were 
added to the cells and incubated for 1 hour at 37°C. Cells 
were then washed three times with PBS and fixed with 4% 
paraformaldehyde for 30 minutes. After washing, the cover 
slips were mounted on microscope slides and observed on 
a fluorescence microscope.
Results
Polymeric micelle preparation
Poly(ethylene glycol-b-trimethylsilyl methacrylate), 
which contains silicon moieties that can be cleaved under 
mildly acidic conditions (pH between 5 and 6), was syn-
thesized by Reversible Addition-Fragmentation chain 
Transfer method (Figure 1A). The amphiphilic diblock 
co-polymer (PEG-b-PTMSMA) micelles were designed 
to accommodate the hydrophobic CA (tBuBipyGd) within 
its core and to release its load at the site of interest, via 
the hydrolysis of its silyl ester groups located in the 
hydrophobic moiety of the copolymer in a mildly acidic 
medium, such as cancer tissue.
The tBuBipyGd complex was obtained from the reflux 
of GdCl
3
⋅4H
2
O and tBuBipy in ethanol. The structure 
[GdtBuBipy(H
2
O)
4
(Cl)
2
]Cl was assessed based on the 
literature data for the complex [GdBipy(H
2
O)
4
(Cl)
2
]Cl 
(Figure 1B). Elemental analysis and Fourier transform 
infrared spectroscopy spectrum were in accordance with 
the proposed structure. We chose this complex as a model 
compound because of its hydrophobicity, conferred by the 
tert-butyl group in the bipyridine core, as well as the expected 
strong MR signal due to the high number of coordinated 
water molecules.
In the encapsulation process, tBuBipyGd complex and 
PEG-b-PTMSMA were co-dissolved in DMF and self-
assembly was induced by slow addition of water. Due to 
its hydrophobic nature, the complex tends to lay within the 
micelle core (Figure 1C). Organic solvent was then removed 
by dialysis to yield micelles with the size ranging from 
35 nm to 40 nm (Figure 3A, B). The tBuBipyGd complex 
concentration in micelles determined by spectrophotometry 
was on average of 0.065 mM.
The approximate micelle aggregation number (N
agg
) 
can be calculated from the ratio of the average molecular 
weight of the micelle to the molecular weight of the block 
copolymer. Light-scattering experiments (SLS and DLS) 
indicated that the average molecular weight of the micelle 
is 8.1×104 Da (individual co-polymer weight of around 
9 kDa). Thus, we estimated an aggregation number of 9. 
Accordingly, the maximum number of micelles formed in a 
solution of 1 mL was found to be approximately 4.2×1010. 
By correlating the dye concentration with its absorbance at 
344 nm, we quantified the total number of dye molecules as 
6.3×1015 after they were released into the solution. Because 
we washed off any unencapsulated dye in the solution before 
the destruction of micelles, we can estimate that one micelle 
with an average diameter (Rh=30 nm, N
agg
~9) can load at least 
150,000 dye molecules and around 75,000 Gd(III) complex 
if we assume that the volume of Gd(III) doubles the volume 
of 1-methylpyrene. Therefore, the release of these dye 
molecules into solution should provide a significant signal 
amplification effect for better resolution and sensitivity.
Polymeric micelle stability and selectivity 
study
To test the in vitro stability and uptake of micelles by cells, 
1-methylpyrene fluorophore was loaded into micelles instead 
of tBuBipyGd complex, because of the feasibility of fluo-
rescence detection and quantification in cells. The concen-
tration of 1-methylpyrene in these micelles, as determined 
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by spectrophotometry, was on average of 0.96 mM. In the 
fluorescence spectrum of 1-methylpyrene–loaded micelles 
(Figure 4A), the observation of both monomer (375 nm) 
and excimer (480 nm) emission bands clearly confirms the 
encapsulation of the fluorophore.28 When nonconjugated and 
bioconjugated micelles were diluted in cell culture medium, 
there were no significant changes in the fluorophore fluo-
rescence spectrum (Figure 4A, B, C), which is indicative of 
maintenance of micelle integrity. However, and in spite of 
being stable in aqueous solutions for weeks, when the solu-
tion pH was lowered to values between 5 and 6, a progressive 
release of the fluorophore was observed.28
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Figure 3 (A) Dynamic light-scattering results for loaded polymeric micelles after the encapsulation of the contrast agent. (B) TeM of contrast-loaded polymeric micelles 
after the self-assembly of poly(ethylene glycol-b-trimethylsilyl methacrylate).
Note: Magnification: ×200,000. Bar scale: 50 nm.
Abbreviation: TeM, transmission electron microscopy.
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Figure 4 1-Methylpyrene (MePy) fluorophore-loaded polymeric micelle stability in water and cell culture medium.
Notes: Fluorescence intensity spectra of 1-methylpyrene monomer (375 nm) and excimer (480 nm) was measured to detect disintegrated and intact micelles, respectively, and these 
were found to be stable in (A) water and (B) culture medium. (C) Micelle bioconjugation with the sM3 MUc1 monoclonal antibody did not alter stability in culture medium.
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Determination of Peg-b-PTMsMa 
micelle-based ca imaging ability
The paramagnetic Gd(III) ions in complexes used as CA in 
MRI shorten the relaxation time T
1
 of the water protons in 
their proximity, leading to an increase of the image contrast. 
Therefore, restricting water access to those chelates should 
prevent them from decreasing the T
1
 of the surrounding water 
molecules. As a result, the CA remains switched-off in neutral 
pH but switched-on at acidic pH, which is a typical character-
istic of malignant tumors. This feature was first demonstrated 
in vitro using 1H NMR, where the T
1
 of water protons was 
initially measured in a sample containing intact tBuBipyGd-
loaded micelles and it was found to be 3.4 seconds, but upon 
micelle disruption, by the addition of an acid solution (pH 5.5), 
the T
1
 value dropped to 1.2 seconds (Figure 5A).
Further testing using a clinical MRI was performed. 
This experiment consisted of imaging two microfuge tubes 
containing tBuBipyGd complex–loaded micelle in water, one 
at neutral pH and the second with pH 5.5. The first sample, 
with neutral pH, did not change the background image signal 
and no contrast was observed (Figure 5B, square a), while 
the second tube presented a significant signal enhancement 
visible as a bright area (Figure 5B, square b). These results 
indicate that the micelles disassembled at low pH and released 
the tBuBipyGd complex. Consequently, the complex inter-
acted with the surrounding water molecules and decreased 
the T
1
 relaxation time, which leads to an increase in the 
image signal intensity from that specific area. Together, these 
experiments show the ability of these tBuBipyGd-loaded 
micelles to respond to an acidic condition by changing their 
states (on and off), as indicated by the alteration in T
1
 time 
and image signal intensity.
In vitro cytotoxicity tests
To assess the cytotoxicity of free tBuBipyGd complex, we 
tested its effect on two different human cell lines, the Jurkat 
leukemia cell line and the MCF-7 breast cancer cell line. 
By performing MTT assays, we observed that the median 
lethal dose (LD50) of tBuBipyGd complex for the MCF-7 
and Jurkat cell lines was, respectively, 12.8 μM and 10.2 μM 
(Figure 6A), indicating that the tBuBipyGd complex is toxic 
at the micromolar range. Further cytotoxicity studies dem-
onstrated that encapsulation of tBuBipyGd complex inside 
polymeric PEG-b-PTMSMA micelles greatly decreased its 
toxicity (Figure 6B). The difference in cytotoxicity was most 
evident at 50 μM of tBuBipyGd, the highest concentration 
tested, where most cells treated with encapsulated complex 
for 3 days were still viable, while most cells treated with free 
tBuBipyGd complex were dead (Figure 6B). The observation 
that Gd(III) complex–loaded micelles were not cytotoxic cor-
roborated their observed stability in vitro (Figure 4), because 
neither during dialysis nor during contact with cell culture 
medium there appeared to occur significant release of the 
complex and consequent increased cell death. Cytotoxicity 
tests also showed that up to 1 mg mL-1 of PEG-b-PTMSMA 
micelles alone were not toxic to Jurkat cells (data not shown), 
further supporting the notion that encapsulation of tBuBipyGd 
complex within PEG-b-PTMSMA micelles prevents 
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Figure 5 (A) scheme of 1h NMr relaxometric experiment to measure T1 of water before and after the release of the contrast agent from the polymeric micelles. 
(B) Magnetic resonance image of microfuge tubes containing tBuBipygd complex–loaded micelles, at ph 7 (square a) and at ph 5.5 (square b).
Abbreviation: NMr, nuclear magnetic resonance.
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 cytotoxicity. The observed protection from content toxicity 
provided by our polymeric micelles, an important property 
for their in vivo administration as nanocarriers, should lead 
to reduced or no toxicity to healthy tissues, at least until the 
micelles reach the appropriate acidic microenvironment and 
disassemble. This important feature will open the door to 
new types of dual-function CAs that detect and kill at the 
same time the cancer cells in early stages, these dual-function 
contrasts are currently under investigation in our group.
Targeting of MUc1-expressing breast 
cancer cells by bioconjugated micelles
An important desired feature of the designed micelles, 
besides the pH-sensitive release mechanism, is the ability to 
specifically target cancer cells. To obtain this capability we 
bioconjugated micelles with an antibody against a cell surface 
tumor antigen. For this work, the MUC1 glycoprotein was 
chosen as a target for our new MRI CA because it is often 
overexpressed in human cancers, notably in breast cancer.27 
Furthermore, MUC1 has shown a great potential for early 
detection and staging of tumors, as well as for the assess-
ment of tumor responses to therapy and detection of disease 
recurrence.27 In addition MUC1 has been tested as target for 
quantum dot and gold nanoparticle–mediated cancer diagno-
sis or therapy.31–33 Confirming previously published data,34 
we verified that the MDA-MB-468 and MCF-7 human breast 
adenocarcinoma cell lines, but not the unrelated HEK293T 
cell line, expressed high levels of MUC1 mRNA (Figure 7A) 
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Figure 7 (A) Detection of MUC1 mrNa expression in different cell lines by quantitative rT-Pcr analysis. (B) Detection of MUc1 cell surface expression on McF-7 and 
MDA-MB-468 cell lines by fluorescent flow cytometry using the C595 (green line) and SM3 (pink line) mAbs.
Note: The dark blue shaded region corresponds to the signal obtained with a control nonspecific isotypic antibody.
Abbreviations: mrNa, messenger rNa; rT-Pcr, real-time polymerase chain reaction.
and MUC1 protein at the cell surface (Figure 7B), indicating 
their suitability as cancer models to test our bioconjugated 
micelles. Of two different mAbs tested by flow cytometry, 
SM3 showed higher affinity for surface MUC1 protein in 
both cell lines, indicating its potential to be more suitable for 
breast cancer cell targeting (Figure 7B).
To test the ability of bioconjugated micelles to 
target breast cancer cells, we loaded micelles with the 
1-methylpyrene fluorophore instead of tBuBipyGd complex, 
because of the fast and ready detection by microscopy of 
internalized fluorescence in targeted cells. After 1 hour 
incubation with micelles loaded with this fluorophore, fol-
lowed by unbound micelle removal, cells were observed on 
a fluorescence microscope. Thus, MCF-7 cells incubated 
with C595  anti-MUC1–conjugated micelles presented more 
fluorescent staining than cells incubated with nontargeted 
micelles, in which no specific fluorescence was observed 
(Figure 8A). C595-conjugated micelles targeted both MCF-7 
and MDA-MB-468 breast cancer cells, but micelles conju-
gated with the higher affinity SM3 mAb conferred increased 
fluorescence to target cells (Figure 8B). Together, these 
results demonstrated the specificity of the targeted micelles 
to MUC1-expressing cells and demonstrated that micelles 
released their content within cells.
Next we used another approach to test the targeting 
specificity of anti-MUC1 micelles. The goal was to observe 
whether anti-human MUC1 micelles were able to specifi-
cally target MDA-MB-468 cells, even when these cells were 
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Figure 8 Targeting of anti-MUc1 bioconjugated micelles to breast cancer cell lines.
Notes: (A) Specific binding of C595 anti-MUC1 1-methylpyrene–loaded micelles to MCF-7 breast cancer cells. After washing three times, high 1-methylpyrene fluorescence 
signal was found in cells incubated with polymeric micelles conjugated with C595 monoclonal antibody, while a low level of background fluorescence was visible in MCF-7 
cells incubated with nontargeting micelles. (B) Targeting of c595 and sM3 anti-MUc1 1-methylpyrene–loaded micelles to MDa-MB-468 breast cancer cells.
mixed in a lower proportion (1:5) with unrelated cells from 
another species, the mouse S17 bone marrow stromal cell 
line. By incubating this mixed culture with anti-MUC1 
polymeric micelles, we observed that MDA-MB-468 cells, 
which display spherical morphology, incorporated far more 
1-methylpyrene fluorescence than S17 cells (Figure 9). In 
this experiment little fluorescence of the elongated mor-
phology cells (S17) was observed, in contrast to the larger 
and brighter spots in round-shaped MDA-MB-468 cells 
(Figure 9A).
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Figure 9 Increased targeting of anti-MUc1 1-methylpyrene–loaded micelles to MDa-MB-468 breast cancer cells.
Notes: (A) MDa-MB-468 and s17 cells cultured together in a 1:5 proportion were incubated for 1 hour with c595 mab–bioconjugated micelles. (B) Bright field microscopy 
of MDa-MB-468 cells. (C) Brigth field microscopy of S17 cells.
Discussion
The present study reports the development of a smart CA 
composed of pH-sensitive micelles containing a hydrophobic 
Gd(III) complex with the aim of specifically detecting cancer 
by MRI. Two main features confer high specificity for these 
CAs to detect cancer tissues: (i) pH sensitivity, which leads 
to a contrast signal only in acidic microenvironments, and 
(ii) antibody conjugation, which leads to preferential targeting 
to tumor tissues expressing the respective antigen.
Our experiments demonstrated that when encapsulated 
in these micelles, the CA remained in the off state, being 
activated only upon micelle disruption in an acidic medium. 
Several researchers have reported pH-sensitive particles 
such as liposomes with the aim of detecting cancer tissues 
or other acidic pathologic areas by MRI.7–13 However, pH 
sensitivity was the only feature in these tools for cancer 
targeting, besides the enhanced permeability and retention 
effect.25 Other researchers have developed nanoparticles 
conjugated to biomolecules (eg, antibody or peptides) to tar-
get and image cancer.35,36 Our results with MUC1-expressing 
cell lines indicate that the conjugation of self-assembled 
polymeric micelles with a tumor-specific mAb increases 
significantly their affinity toward cancer cells. Therefore, 
our bioconjugated pH-sensitive micelles present two features 
enabling targeting and imaging of cancer. This characteristic 
is instrumental for the application of these smart micelles as 
carriers to deliver CAs to MUC1-expressing cancer tissues. 
In this work we have tested two mAbs targeting the MUC1 
surface protein, often overexpressed in mammary and other 
adenocarcinomas, such as gastric, colorectal, lung, prostate, 
ovarian, pancreatic, and bladder cancers.26,27 The C595 mAb, 
which reacts with the tetrameric motif RPAP present on 
the tandem repeats in the extracellular region of the MUC1 
protein, has already been proven to be an efficient and 
specific targeting vector in preclinical and clinical trials of 
radioimmunoscintigraphy and radioimmunotherapy.37,38 The 
SM3 mAb reacts against the APDTRP sequence, which is 
exposed only in underglycosylated MUC1 protein.26 Because 
underglycosylated MUC1 is very frequent and specific for 
breast and other epithelial cancers,26 the SM3 mAb should 
be highly suitable to conjugate the micelles to target can-
cer tissues. The possibility of conjugating our polymeric 
micelles with other antibodies specific for different tumor 
antigens should enable their application to a wide range of 
human cancers. The identification of cancer biomarkers is 
an area of intense research, so novel cell surface biomarkers 
may become potential targets for our nanoparticle-based 
smart CAs.
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Conclusion
The presented work demonstrated that the developed poly-
meric micelle-based CA is able to turn on its imaging ability 
upon a pH decrease. The encapsulation of the active complex 
within micelles decreased its toxicity and allows the use of 
small amounts of CA (1.08 μmol kg-1) in the clinic, as com-
pared to current protocols, to avoid potential side effects. 
These features allied with the finding that micelle conjuga-
tion with an antibody specific for a tumor antigen increased 
their uptake by cancer cells and with their small size, turns 
this polymeric nanoparticles into a promising new tool for 
cancer early detection by MRI.
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